Drug Profile
BIA 123126
Alternative Names: BIA 12 3126; BIA-12Latest Information Update: 12 Apr 2022
Price :
$50
*
At a glance
- Originator Bial
- Developer BIAL
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glaucoma
Most Recent Events
- 12 Apr 2022 BIA 123126 is still in preclinical development for Glaucoma in Portugal (BIAL pipeline, April 2022)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Glaucoma in Portugal
- 30 Oct 2017 Preclinical trials in Glaucoma in Portugal before October 2017 (BIAL pipeline, October 2017)